Skip to main content

Calidi Biotherapeutics, Inc.

corporate_fare Company Profile

Calidi Biotherapeutics, Inc.

CLDI·NYSE·Life Sciences·CIK 0001855485

Calidi Biotherapeutics, Inc. is a publicly traded biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. Its proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. This enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to reach tumor sites, induce tumor lysis, and deliver genetic medicines to metastatic locations. The company expects to file an investigational new drug (IND) application for a Phase I trial by the end of 2026 with CLD-401, the first compound from the RedTail platform, delivering IL-15 superagonist to the tumor microenvironment (TME). The RedTail platform is the culmination of over a decade of work around genetic engineering of viruses and allows for systemic administration of a proprietarily-modified oncolytic virus that can survive in circulation and home to metastatic tumor sites; only replicate in tumor cells; induce immunogenic kill in tumor cells and immune priming in the TME; and deliver genetic medicine payloads like IL-15 superagonist for expression in the TME. The company's legacy SuperNova and NeuroNova stem cell based oncolytic virus platforms are designed to protect oncolytic viruses from neutralizing antibodies and complement inactivation and innate immune cell inactivation; enhance oncolytic viral amplification inside the allogeneic cells; and modify the TME to allow improvements in cell targeting and viral amplification at the tumor site. Oncolytic viruses have been pursued as therapeutic platforms in oncology because of their ability to preferentially infect and replicate within cancer cells, resulting in direct lysis of tumor cells and activation of an antitumor immune response while leaving normal, healthy cells unharmed. A major obstacle has been their rapid elimination by the patient's immune system, which has largely relegated oncolytic viruses to local delivery to tumors rather than successful use in patients with extensive metastatic disease.

Calidi Biotherapeutics, Inc. (NYSE:CLDI) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 2 items for CLDI at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 8/10. Across its 2 most recent items scored 7 or higher, the top rating is 8/10, with 1 rated 8 or above. Recent SEC coverage for CLDI spans 10-Q, 8-K.

Recent high-impact activity:

  • Calidi 10-Q Discloses Going-Concern Doubt, NYSE Equity Deficiency and Executive Pay Deferrals
  • Calidi Posts $3.6M Q3 Loss, Cuts 39% of G&A, Executes $3M Restructuring to Extend Runway

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$19.91M
Diluted EPS
-$5.95
Op. Cash Flow
-$21.29M
Operating Income
-$20.24M
Cash & Equivalents
$5.6M
Total Debt
$690K
Debt / Equity
0.18×
Shares Outstanding
7.22M sh
Source: 10-K · filed 2026-03-27 · accession 0001493152-26-013242

Short Interest & Short Volume

2.48 days to cover

FINRA reported short interest of 135,691 shares in CLDI as of the October 30, 2026 settlement, a 17.4% decrease from the prior period — about 2.5 days to cover at its recent average daily volume. On November 20, 2026, 21.8% of CLDI volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)135,691 shares as of October 30, 2026
Change vs prior period▼ 17.4%
Days to cover2.48 at avg daily volume of 54,754
Daily short volume (FINRA facilities)21.8% of 32,398 shares on November 20, 2026
5-day average short volume32.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

$0.4652 -2.58% today
52-week range · as of 2026-11-13 $0.4652 – $24.96
Market cap
$1.65M
Volume
47.8K (1.1× avg)
3-mo avg 43.8K
Live data · 2026-11-21 02:55 UTC · Market overnight

show_chartPrice Chart

Loading chart...

feed CLDI - Latest Insights

CLDI
Nov 13, 2026, 5:00 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.6219
Real-time Price: $0.4652 info
Change: -$0.1567 (-25%) info
Market Cap: $1.647M info
CLDI
Nov 13, 2026, 4:35 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.6219
Real-time Price: $0.4652 info
Change: -$0.1567 (-25%) info
Market Cap: $1.647M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets